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Abstract
Cluster-randomized trials are often conducted to assess vaccine effects. Defining
estimands of interest before conducting a trial is integral to the alignment between
a study’s objectives and the data to be collected and analyzed. This paper consid-
ers estimands and estimators for overall, indirect, and total vaccine effects in trials
where clusters of individuals are randomized to vaccine or control. The scenario is
considered where individuals self-select whether to participate in the trial and the
outcome of interest is measured on all individuals in each cluster. Unlike the over-
all, indirect, and total effects, the direct effect of vaccination is shown in general not
to be estimable without further assumptions, such as no unmeasured confounding.
An illustrative example motivated by a cluster-randomized typhoid vaccine trial is
provided.
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1 INTRODUCTION
Vaccines are integral to combating a variety of infectious diseases. Quantifying a vaccine’s effects is vital to determining
its benefits, which can then guide public health policies aimed at reducing the burden of disease. Cluster-randomized tri-
als are often conducted to quantify the effects of a treatment or intervention such as a vaccine. In cluster-randomized trials,
individuals are grouped together based on certain characteristics (e.g., neighborhood of residence), and the entire cluster is
randomized to treatment or control. The process of randomization ensures that the treatment and control groups are exchange-
able. Cluster-randomization is useful when it is impractical or infeasible to randomize at the individual level1. Comparisons
between randomized clusters can be used to assess the overall impact of an intervention on the population, which is particu-
larly important in settings where an intervention may have indirect (or spillover) effects2. For example, in the infectious disease
setting, whether one individual is vaccinated could affect the outcome of another individual. Moulton et al.3 describe a cluster-
randomized trial in the White Mountain Apache Reservation and the Navajo Nation wherein approximately 9000 infants within
ar
X
iv
:1
91
0.
03
67
5v
1 
 [s
tat
.M
E]
  8
 O
ct 
20
19
2 Kilpatrick ET AL.
38 clusters were randomized by cluster to the vaccine of interest (Streptococcus pneumoniae conjugate vaccine) or control (a
meningococcal C conjugate vaccine). Diallo et al.4 present a cluster-randomized trial of an inactivated influenza vaccine in Sene-
gal in which approximately 7800 enrolled, age-eligible children within 20 clusters were randomized by cluster to the influenza
vaccine or control (an inactivated polio vaccine). Sur et al.5 describe a cluster-randomized trial of a typhoid vaccine in India,
with approximately 38000 individuals within 80 clusters randomized by cluster to the typhoid vaccine or control (hepatitis A
vaccine).
Because the cluster-randomized trial is a common study design for evaluating vaccine effects, it is important to carefully
define the estimands, i.e., parameters of interest, in these trials. Careful definition of the effects of interest prior to the study
can aid in study planning and can ensure that the study’s goals are achieved6. Recently, there has been increased interest in
defining estimands in clinical trials. The International Council on Harmonization (ICH) has published a draft addendum to
the E9 guidelines detailing the use of estimands in clinical trials and is currently in the process of refining and finalizing the
addendum7. This addendum aims to describe the necessity of defining the target estimand before the design and analysis of trials
to avoid misalignment of the trial goals and the data, as well as to ensure that estimation of the estimand is possible without
relying upon dubious assumptions8.
Leuchs et al.6, Koch and Wiener9, Permutt10, and Phillips et al.11 discuss examples of estimands of interest in regulatory
clinical trials. Target estimands specifically for cluster-randomized trials have been previously considered for certain designs.
Wu et al.12 consider estimands for matched-pair cluster-randomized trials. Hudgens and Halloran13 consider estimands of the
direct, indirect, total, and overall effects of treatment assuming a two-stage randomization scheme. In this design, clusters are
randomly assigned to a treatment allocation program, and individuals within the clusters are randomly assigned to treatment
based on the cluster-level assignment. In some cluster-randomized trials, individuals may not comply with their randomization
assignment or may choose not to participate in the study3,5,14,15. Frangakis et al.16 consider clustered encouragement designs,
which allow noncompliance, where individuals belong to one of three principal strata: always-takers, compliers, and never-
takers. Kang and Keele17 also consider cluster-randomized trials with noncompliance. Like Frangakis et al.16, they consider
the setting where there are the three principal strata mentioned above, and also the special case where there are no always-
takers. Even for this special case, they show the total and indirect (spillover) effects are not identified because principal strata
membership is unknown for some individuals.
In this paper, we consider cluster-randomized vaccine trials where individuals choose whether or not to participate in the
trial. As illustrated by the examples described above, it is common in cluster-randomized vaccine trials for the control to be
another vaccine which is not expected to affect the outcome of interest. For simplicity, below the control vaccine will sometimes
be referred to just as a control. Here we consider the particular case where a control vaccine is employed and individuals are
blinded, i.e., unaware whether their cluster is randomly assigned to the vaccine of interest or to the control vaccine. In this
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setting, it is reasonable to assume individual participation behavior is unaffected by randomization, such that there are only
two principal strata: always participators and never participators. Thus, our setting is similar to the special case considered by
Kang and Keele17. However, because it is assumed an individual will participate or not in the trial regardless of randomization
assignment, principal strata membership is known for all individuals; this allows for identification and estimation of overall,
total and indirect effects.
Sur et al.5 provides a motivating example of a cluster-randomized vaccine trial where individuals self-select whether to
participate. In this trial, clusters of individuals were randomized to either a typhoid vaccine or a control vaccine (for hepatitis
A). The presence of a control allowed study blinding, so individuals in the clusters did not know which assignment their cluster
received. While some individuals chose not to participate in the trial, outcome data was collected on all individuals. This allows
inference about different effects of the vaccine, as described below.
The outline of the remainder of this paper is as follows. In Section 2, notation, estimands, estimators, and effects of interest
are described. In Section 3, the Sur et al.5 cluster-randomized typhoid vaccine trial is considered. Finally, Section 4 concludes
with a discussion.
2 METHODS
2.1 Notation and Potential Outcomes
Consider a cluster-randomized vaccine trial with 푛 clusters (or groups) of individuals where each cluster is randomly assigned
to vaccine or control. For 푖 = 1,… , 푛, let 퐴푖 = 1 if cluster 푖 is assigned to vaccine and 퐴푖 = 0 otherwise. Let 푌 푎=1푖 denote
the potential outcome if cluster 푖 is assigned vaccine, and let 푌 푎=0푖 denote the potential outcome if cluster 푖 is assigned control.
For example, 푌 푎=1푖 could denote the proportion of individuals in cluster 푖 who would develop typhoid within one year after
randomization if, possibly counter to fact, cluster 푖were assigned to vaccine. For now, we leave the particular outcome associated
with 푌 푎푖 unspecified. Different specifications of 푌 푎푖 will correspond to different vaccine effects, as described below. Let 푌푖 denote
the observed outcome for cluster 푖, such that 푌푖 = 푌 푎=1푖 퐴푖 + 푌 푎=0푖 (1 − 퐴푖). Below, the subscript 푖 is sometimes dropped for
notational convenience.
In cluster-randomized vaccine trials, one individual’s vaccination status may affect another individual’s outcome, that is, there
may be “interference" between individuals18. For instance, if one individual receives a typhoid vaccine, this could affect whether
or not another individual develops typhoid. Throughout this paper, it is assumed that there is no interference between individuals
in different clusters, i.e., there is “partial interference"19. Under this assumption, the outcome 푌푖 for cluster 푖 depends only on
the treatment assigned to cluster 푖. No assumption is made regarding the form of interference within clusters.
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2.2 Estimands and Estimators
Vaccine effects, i.e., the causal effects of vaccination, can be defined by contrasts in the expected values of the potential outcomes
푌 푎=1 and 푌 푎=0. Assuming the 푛 clusters in the trial are randomly sampled from an infinite super-population of clusters, the
average treatment (vaccine) effect is generally defined by
휃 = 퐸[푌 푎=1] − 퐸[푌 푎=0] (1)
where 퐸[푋] denotes the expected value of 푋 in the super-population of clusters. In words, (1) is the difference in the average
outcome in the super-population when a cluster receives 푎 = 1 compared to when a cluster receives 푎 = 0. Alternatively,
the 푛 clusters could be considered the finite population of interest and 퐸[푋] defined instead to be 푛−1∑푛푖=1푋푖. The super-
population perspective is adopted in this paper, but similar considerations to those provided here apply if the finite population
approach is utilized instead. Likewise, estimands other than (1) could be considered. For example, for binary 푌 , the risk ratio
퐸[푌 푎=1]∕퐸[푌 푎=0] = Pr[푌 푎=1 = 1]∕ Pr[푌 푎=0 = 1] might be of greater interest than the risk difference (1). More generally,
causal effects can by defined by 푔(퐸[푌 푎=1], 퐸[푌 푎=0]) for some contrast function 푔(푥, 푦) where 푔(푥, 푥) = 0; e.g., 푔(푥, 푦) = 푥− 푦
corresponds to (1). Below, estimands of the form (1) are described, but similar considerations apply for other contrasts.
A few aspects of defining causal effects bear mentioning. First, causal effects are typically defined by contrasts in expected
values of the potential outcomes over the same set of units20,21. In many settings, the unit is defined to be an individual; for
example, a unit could be a participant in a randomized controlled trial. Here, we consider the clusters to be the units since
randomization is at the cluster level. Note that contrasts in average potential outcomes between different sets of units do not
have a causal interpretation. For example, suppose a cluster-randomized vaccine trial is conducted in schools, where students
within the same school constitute the clusters. A comparison of the average 푌 푎=1 among clusters (schools) in rural areas to the
average 푌 푎=0 among clusters in urban areas is not a causal effect. Also note that causal effects are contrasts in the expected
value of the same outcome under different counterfactual scenarios. Contrasts in different outcomes are not causal effects. For
example, a comparison of the average incidence of typhoid when clusters receive vaccine with the average incidence of cholera
when clusters receive control would not be a causal effect. We will revisit this point below when discussing direct effects.
The average treatment effect can be estimated by the difference in sample means:
휃̂ =
∑푛
푖=1 푌푖퐼(퐴푖 = 1)∑푛
푖=1 퐼(퐴푖 = 1)
−
∑푛
푖=1 푌푖퐼(퐴푖 = 0)∑푛
푖=1 퐼(퐴푖 = 0)
(2)
This estimator is consistent and unbiased under commonly used randomization schemes, such as a completely randomized
experiment where the number of clusters assigned vaccine (treatment) is fixed22,23,24. The standard error of 휃̂ can be estimated
and 95% Wald confidence intervals can be constructed in the usual manner for the difference in means. Equivalently, (2) can be
obtained by computing the least squares estimate of the slope parameter of simple linear regression of 푌 on퐴. A generally more
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precise estimator can be obtained by regressing 푌 on 퐴 and 푍 where 푍 is some vector of baseline covariates. For simplicity,
only estimators of the form (2) are considered below; see Tsiatis et al.25 for further discussion on using baseline covariates to
improve efficiency.
2.3 Overall, Indirect, and Total Effects
In this section, the general approach above is used to define estimands and estimators of the overall, indirect, and total effects.
The outcome of interest will depend on the context of the vaccine trial, such as the infection or pathogen of interest, the target
population, and so forth. Here, the outcome of interest is generically referred to as disease.
The overall effect compares the average disease outcome among all individuals when a cluster is assigned vaccine versus
when a cluster is assigned control. This quantity may be the most relevant to public health policy because all individuals within
clusters are used in the comparison. As it is likely that populations of interest will include a mixture of individuals who would
and who would not choose to be vaccinated, the overall effect may be valuable for public health officials and policy makers in
assessing the overall impact of a vaccine at the population level.
The overall effect estimand and estimator can be defined in terms of individual level outcomes as follows. Let 푚푖 denote the
number of individuals in cluster 푖. For individual 푗 in cluster 푖, let 푌푖푗 = 1 if individual 푗 develops disease, and let 푌푖푗 = 0
otherwise. Let 푌 푎=1푖푗 indicate the outcome that would have been observed for individual 푗 if cluster 푖 is randomized to vaccine,
and define 푌 푎=0푖푗 analogously for control, such that 푌푖푗 = 푌 푎=1푖푗 퐴푖 + 푌 푎=0푖푗 (1 − 퐴푖). For the overall effect, the estimand (1) can
be expressed in terms of individual potential outcomes by defining 푌 푎=1푖 =
∑푚푖
푗=1 푌
푎=1
푖푗 ∕푚푖, and 푌 푎=0푖 =
∑푚푖
푗=1 푌
푎=0
푖푗 ∕푚푖 for
cluster 푖. The overall effect estimator can likewise be expressed in terms of the observed individual-level outcomes by letting
푌푖 =
∑푚푖
푗=1 푌푖푗∕푚푖.
The indirect effect quantifies the effect of vaccination on individuals who chose not to participate in the trial and, therefore,
have no chance of receiving the vaccine. This effect is defined as a contrast in the average outcomes among non-participants
when their cluster does or does not receive vaccine26. Because the indirect effect is defined only among individuals who never
receive the vaccine, this effect (if present) is solely due to interference. Thus, indirect effects are a type of spillover or peer
effect19. Quantifying indirect effects may be of interest from a public health policy perspective because vaccinating some, but
not all, individuals within a cluster can still provide benefits to those who are unable or choose not to be vaccinated.
Like the overall effect, the indirect effect estimand and estimator can be defined in terms of individual level outcomes. To do
so, first define the potential outcome 푆푎=1푖푗 where 푆푎=1푖푗 = 1 if individual 푗 in cluster 푖 would choose to participate in the trial
if, possibly counter to fact, cluster 푖 were randomized to vaccine and 푆푎=1푖푗 = 0 otherwise. Define 푆푎=0푖푗 analogously. Denote the
observed participation outcome for individual 푗 in cluster 푖 by 푆푖푗 , such that 푆푖푗 = 푆푎=1푖푗 퐴푖+푆푎=0푖푗 (1−퐴푖). Assume 푆푎=1푖푗 = 푆푎=0푖푗 ,
i.e., an individual’s decision to participate is not affected by whether their cluster is assigned vaccine or control. This assumption
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may be reasonable in cluster-randomized trials where individuals are blinded, such as the typhoid vaccine trial described in
Section 3, because in such settings, randomization is not expected to have an effect on an individual’s decision to participate in
the trial. As mentioned in the Introduction, Frangakis et al.21 and Kang and Keele17 utilize the principal stratification framework
when considering non-compliance in cluster-randomized trials. Under the assumption푆푎=1푖푗 = 푆푎=0푖푗 , all individuals belong to one
of two principal strata: always participators, i.e., individuals where 푆푎=1푖푗 = 푆푎=0푖푗 = 1; and never participators, i.e., individuals
where 푆푎=1푖푗 = 푆푎=0푖푗 = 0. Fortunately, unlike the setting considered by Kang and Keele, here the principal strata membership of
each individual can be inferred directly from the observed data because 푆푖푗 = 푆푎=1푖푗 = 푆푎=0푖푗 .
The indirect effect is the effect of vaccine in the non-participator principal stratum. The indirect effect has the
general form (1), with 푌 푎=1푖 now defined to be
{∑푚푖
푗=1 푌
푎=1
푖푗 퐼(푆
푎=1
푖푗 = 0)
}
∕
{∑푚푖
푗=1 퐼(푆
푎=1
푖푗 = 0)
}
and 푌 푎=0푖 defined to
be
{∑푚푖
푗=1 푌
푎=0
푖푗 퐼(푆
푎=0
푖푗 = 0)
}
∕
{∑푚푖
푗=1 퐼(푆
푎=0
푖푗 = 0)
}
. This estimand compares the average disease outcome among non-
participators when a cluster is assigned vaccine versus when a cluster is assigned control. Similarly, the indirect effect estimator
can be expressed by (2) with 푌푖 defined to be
{∑푚푖
푗=1 푌푖푗퐼(푆푖푗 = 0)
}
∕
{∑푚푖
푗=1 퐼(푆푖푗 = 0)
}
.
The total effect measures the effect of treatment in the always participator principal stratum. Because always participators
receive the vaccine if and only if their cluster is assigned vaccine, the total effect encompasses both the individual effect of
receiving the vaccine as well as the effect of other individuals in the cluster being vaccinated. The total effect estimand and
estimator have the same form as the indirect effect estimand and estimator described above, but with 푆푎=1푖푗 = 0 replaced by
푆푎=1푖푗 = 1, 푆푎=0푖푗 = 0 replaced by 푆푎=0푖푗 = 1, and 푆푖푗 = 0 replaced by 푆푖푗 = 1. The total effect quantifies the difference in
the average disease outcome among always participators when a cluster is assigned vaccine versus when a cluster is assigned
control. The total effect is often the effect of primary interest in this type of trial. An illustration of the overall, indirect, and total
effects is given in Figure 1.
There are a few special cases of note. In the scenario where all individuals in the population are willing to participate in trials
(i.e., there are no non-participators), the indirect effect is not well-defined, and the total and overall effects are equivalent. In
some trials, only a subset of individuals may be eligible to be randomized for vaccination. For example, in Sur et al.5, individuals
were eligible if they were at least two years of age, were not pregnant or lactating, and did not have an elevated temperature
when the vaccine was given. Indirect effects, analogous to that defined above for non-participators, can be defined and estimated
in these individuals if their outcome of interest is measured.
2.4 Direct Effect
The overall, indirect, and total effects each describe an effect of treatment (vaccination) which is at least partially due to interfer-
ence, if present. The effect of treatment that is not attributable to interference may also be of interest. Such an effect is sometimes
referred to as a direct effect. This section describes why it is not possible in general to estimate the direct effect of vaccination
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FIGURE 1 Cluster counterfactual comparisons. The left circle represents a cluster if, possibly counter to fact, assigned to
vaccine (퐴 = 1). The right circle represents a cluster if, possibly counter to fact, assigned to control (퐴 = 0). Within each circle,
푆 indicates which individuals chose to participate in the study (푆 = 1 indicates participation, 푆 = 0 otherwise). The overall,
indirect, and total effects are contrasts in average potential outcomes over different sets of individuals within the clusters.
in a cluster-randomized trial with self-selection of participation without additional assumptions, such as no unmeasured con-
founding. Informally, the direct effect compares the average outcome when an individual is vaccinated to the average outcome
when an individual is not vaccinated, holding fixed the proportion of other individuals vaccinated26. Several formal definitions
of the direct effect estimand have been proposed; e.g., see Hudgens and Halloran13,VanderWeele and Tchetgen Tchetgen27, Liu
et al.28, Eck et al.29 and Sävje et al.30.
Naively, it might be tempting to estimate the direct effect by comparing the proportion of vaccinated individuals with disease
to the proportion of unvaccinated individuals with disease in clusters assigned to vaccine, i.e., by
1∑푛
푖=1 퐼(퐴푖 = 1)
푛∑
푖=1
∑푚푖
푗=1 푌푖푗퐼(푆푖푗 = 1)∑푚푖
푗=1 퐼(푆푖푗 = 1)
퐼(퐴푖 = 1) −
1∑푛
푖=1 퐼(퐴푖 = 1)
푛∑
푖=1
∑푚푖
푗=1 푌푖푗퐼(푆푖푗 = 0)∑푚푖
푗=1 퐼(푆푖푗 = 0)
퐼(퐴푖 = 1). (3)
However, (3) converges in probability to
퐸[푌 푎=1] − 퐸[푌̃ 푎=1] (4)
where 푌 푎=1푖 =
{∑푚푖
푗=1 푌
푎=1
푖푗 퐼(푆
푎=1
푖푗 = 1)
}
∕
{∑푚푖
푗=1 퐼(푆
푎=1
푖푗 = 1)
}
and 푌̃ 푎=1푖 =
{∑푚푖
푗=1 푌
푎=1
푖푗 퐼(푆
푎=1
푖푗 = 0)
}
∕
{∑푚푖
푗=1 퐼(푆
푎=1
푖푗 = 0)
}
.
The estimand (4) is not a causal effect, as it comprises a comparison of different cluster-level outcomes, namely 푌 푎=1푖 and
푌̃ 푎=1푖 . As noted above, for an estimand to have a causal interpretation, the same outcome must be compared under different
counterfactual scenarios.
It is conventional, although not incontrovertible31, to define causal effects only for a treatment or exposure that is manipulable,
i.e., there can be “no causation without manipulation”32. If this convention is followed, then in cluster-randomized trials with
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non-participation, the direct effect of vaccination would only be considered well defined in always participators. Otherwise,
to define the relevant potential outcomes would require considering a counterfactual scenario where non-participators receive
vaccine. However, for the study design under consideration, always participators receive vaccine if and only if other always
participators in their cluster also receive vaccine. Thus it is not possible to observe both (i) a vaccinated always participator
and (ii) an unvaccinated always participator, while holding fixed the proportion of other individuals who are vaccinated in the
cluster; hence the direct effect is not identifiable without additional assumptions.
On the other hand, if the “no causationwithoutmanipulation” convention is not adopted, there are other complications thatmay
arise with estimating the direct effect. In particular, in cluster-randomized trials with non-participation, vaccine coverage within
a cluster is dictated by the collective level of individual participation in the study, which is not under the investigator’s control.
Factors associated with participation may also be associated with the outcome of interest, creating the potential for confounding.
Thus causal inference methods for observational studies, such as those assuming no unmeasured confounding, would in general
be necessary to draw inference about direct effects, e.g., see Tchetgen Tchetgen and VanderWeele33, Perez-Heydrich et al.34.
3 TYPHOID VACCINE TRIAL
A cluster-randomized study was conducted to investigate the effectiveness of a Vi polysaccharide typhoid vaccine in Kolkata,
India over two years of follow-up from 2004 to 20065. The control in this trial was an inactivated hepatitis A vaccine. Geographic
mapping and a census that characterized and counted all people and households in the study area were used to define 80 clusters.
For purposes of randomization, clusters were stratified byward (an administrative unit of Kolkata) and by the number of residents
in certain age groups. Overall, 40 clusters were assigned to Vi vaccine and the other 40 to control. Because data from the typhoid
trial are not publicly available, a simulated data set was constructed (see Supporting Information). The data were simulated to
match exactly the cluster level summary statistics from the actual trial shown in Table 1.
TABLE 1 Summary statistics of a cluster-randomized study in Kolkata from 2004 to 2006 of a Vi typhoid vaccine versus a
hepatitis A control vaccine.5
Typhoid Vaccine Control
Number of clusters 40 40
Mean ± SD* of people per cluster 777 ± 136 792 ± 142
Mean ± SD of participants per cluster 472 ± 103 470 ± 104
Number of participants 18869 18804
Number of non-participants 12206 12877
Number of events in participants 34 96
Number of events in non-participants 16 31
*Standard deviation.
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Sur et al.5 measure vaccine effects in terms of hazard ratios. However, causal interpretations for hazard ratios are difficult
because hazard ratios can depend on time and have an inherent selection bias35. In particular, time-specific hazard ratios compare
different subsets of subjects and, as noted above, estimands have a causal interpretation only when comparing potential outcomes
between the same set (or subset) of units. Due to these issues, instead of using the hazard ratio to determine the vaccine effects
as in Sur et al.5, the risk difference of typhoid over two years is calculated here to quantify vaccine effects.
The overall, indirect, and total effects were estimated using (2) with the 푌푖 definitions provided in section 2.3. The effect
estimates, estimated standard errors (SEs), and 95% Wald confidence intervals (CIs) are shown in Table 2. On average, over
the study period of two years, Vi clusters had 1.61 cases of typhoid per 1000 people, while control clusters had 4.10 cases of
typhoid per 1000 people. The overall effect estimate is -2.49 cases per 1000 people with 95% CI (-3.41, -1.58). The overall
effect estimate has a straightforward interpretation which may be of interest to public health officials such as epidemiologists.
In particular, the number of cases of typhoid per 1000 persons over a two year period is estimated to decrease by 2.5 on average
when a cluster receives the Vi vaccine compared to receiving control.
Both participants and non-participants appear to benefit from the Vi vaccine. In particular, the total effect estimate is -3.30
(95% CI -4.61, -1.99), indicating that assigning a cluster to Vi vaccine causes 3.3 fewer cases of typhoid per 1000 participants
compared to assigning a cluster to hepatitis A vaccine. Likewise, the indirect effect estimate suggests that assigning a cluster to
the typhoid vaccine results in 1.29 (95% CI 0.19, 2.38) fewer cases per 1000 non-participants; as non-participants never receive
the vaccine, this indicates an indirect (or herd immunity) effect of the typhoid vaccine.
TABLE 2 Estimates of overall, indirect, and total effects, standard errors (SE), and 95% Wald confidence intervals (CI). Effect
estimates are differences in typhoid cases per 1000 people per two years.
Effect Estimate (SE) 95% CI
Overall -2.49 (0.47) (-3.41, -1.58)
Indirect -1.29 (0.56) (-2.38, -0.19)
Total -3.30 (0.67) (-4.61, -1.99)
On the other hand, the naive direct effect estimator (3) equals 0.56 (95% CI -0.44, 1.55). Although not statistically significant,
this point estimate implies that the average number of cases of typhoid per 1000 people is higher in vaccinated individuals
compared to non-vaccinated individuals in clusters randomized to the Vi vaccine. However, as described above, this estimate
cannot be interpreted as an effect of the vaccine because it does not account for possible confounding. For example, perhaps
individuals at higher risk of typhoid chose to participate in the trial, or those who participated tended to have different health care
seeking behavior. Moreover, the average number of cases of typhoid per 1000 people was also higher in participants compared to
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non-participants (2.57, 95% CI 1.19, 3.96) in the control clusters, providing direct evidence of confounding. Sur et al.5 reported
similar results, with incidence of typhoid higher in participants compared to non-participants, both within Vi vaccine clusters
and within control clusters.
4 DISCUSSION
Randomized controlled trials are the gold standard in vaccine trials since randomization ensures that the vaccine and control
groups are comparable. Carefully defining estimands in clinical trials is vital to ensure accurate interpretation of the resulting
treatment effect estimates. Because cluster-randomized trials can be large and expensive to conduct, it is important to formally
characterize estimands for use in these trials. This paper considers causal estimands in cluster-randomized trials where inter-
ference may be present within clusters. An illustrative example is provided motivated by a recent cluster-randomized typhoid
vaccine trial demonstrating inference and interpretation of the overall, total, and indirect effect estimands. These types of analyses
can be used to inform public health policies regarding vaccination.
In cluster-randomized trials with self-selection, estimators of the direct effect must account for possible confounding. A stan-
dard method to adjust for confounding is to condition on covariates and assume that conditional on these covariates, participants
and non-participants are exchangeable. A possible indirect way to adjust for confounding could involve comparing outcomes
between participants and non-participants in the control clusters as an estimate of the confounding bias, if present, similar to
negative control approaches described in Lipsitch et al.36 and Tchetgen Tchetgen37. Alternatively, two-stage randomized designs
could be considered to eliminate possible confounding when drawing inference about the direct effect. In two-stage random-
ized experiments, clusters are first randomly assigned to a treatment allocation program, then individuals within those clusters
are assigned to treatment or control based on their cluster’s treatment allocation program13. Randomization eliminates possi-
ble confounding at the cluster and individual level, such that direct, indirect, total, and overall effects can be estimated13,38,39.
However, it may not always be feasible to conduct two-stage randomized trials. In addition, the effects estimated by a two-stage
randomized experiment are not equivalent to the effects estimated in cluster-randomized trials with participation self-selection
and may have less public health relevance40,41.
Estimated effects may have greater real-world relevance depending on the estimands of interest and characteristics of indi-
viduals in the trials, such as the level of participation. Westreich42 provides several examples of population intervention effects
defined by contrasts in average potential outcomes under different possible interventions on the distribution of treatment. These
population intervention effects may be more germane to real-world policy than the traditional approach of defining causal effects
by comparing average outcomes when all individuals in the population receive treatment versus when no individuals receive
treatment. The estimands described here for cluster-randomized trials with self-selection are examples of population intervention
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effects, to the extent that the participation rate in the trial approximates vaccination uptake should the vaccine under evaluation
become widely available to the public. For example, in Sur et al.5, about 60% of individuals on average chose to be vaccinated
in both Vi and hepatitis A clusters; thus, the overall, total, and indirect effect estimates approximate the effects of vaccinating
60% of the population. Such effect estimates could potentially help inform public health policy decisions regarding vaccination.
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